Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,263,936
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.76
  • Price/Sales 3.97
  • Price/Cash Flow 10.34
  • Price/Book 4.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.26 +5.13%
on 05/08/18
61.00 -3.05%
on 04/24/18
+0.22 (+0.37%)
since 04/18/18
3-Month
52.83 +11.94%
on 04/03/18
61.00 -3.05%
on 04/24/18
+2.85 (+5.06%)
since 02/16/18
52-Week
52.83 +11.94%
on 04/03/18
66.41 -10.95%
on 09/18/17
-4.75 (-7.43%)
since 05/18/17

Most Recent Stories

More News
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

LGND : 194.99 (+2.01%)
AZN : 36.33 (-0.30%)
MRK : 59.14 (+0.12%)
LLY : 82.07 (+0.50%)
Amazon Roundup: Google Ads, Experience Centers, Alexa, Sears

Here are the top stories involving Amazon that sent its shares soaring last week.

GOOGL : 1,069.64 (-1.07%)
AAPL : 186.31 (-0.36%)
JPM : 111.13 (-1.62%)
MRK : 59.14 (+0.12%)
BRK.B : 196.06 (-0.72%)
SHLD : 3.59 (-2.71%)
AMZN : 1,574.37 (-0.47%)
Global Infertility Treatment Market 2018-2022: Key Players are AbbVie, Cook Group, Ferring, Merck, The Cooper Companies & Vitrolife - ResearchAndMarkets.com

The "Global Infertility Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

MRK : 59.14 (+0.12%)
Roche Tecentriq Combo Achieves Longer Overall Survival Rate

Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

MRK : 59.14 (+0.12%)
LLY : 82.07 (+0.50%)
RHHBY : 27.9300 (-0.07%)
PFE : 35.64 (-0.20%)
The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial

The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial

MRK : 59.14 (+0.12%)
HD : 187.42 (+1.13%)
SLF : 43.37 (-0.48%)
RTN : 211.06 (+0.21%)
ETN : 78.59 (+1.18%)
Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development,...

MRK : 59.14 (+0.12%)
SGEN : 56.77 (-0.98%)
AMGN : 176.30 (+0.94%)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated...

MRK : 59.14 (+0.12%)
SNDX : 8.80 (+2.21%)
Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

DARMSTADT, Germany, May 17, 2018 /PRNewswire/ --

MRK : 59.14 (+0.12%)
New Data from Merck's Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting

--First-Time Lynparza(R) (olaparib) Data in Combination with Abiraterone in Metastatic Prostate Cancer Under Merck and AstraZeneca Strategic Collaboration

MRK : 59.14 (+0.12%)
Top Analyst Reports for Home Depot, Merck & Raytheon

Top Analyst Reports for Home Depot, Merck & Raytheon

BBT : 54.91 (-0.94%)
MRK : 59.14 (+0.12%)
SLF : 43.37 (-0.48%)
HD : 187.42 (+1.13%)
RTN : 211.06 (+0.21%)
ETN : 78.59 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 60.67
1st Resistance Point 59.90
Last Price 59.14
1st Support Level 57.93
2nd Support Level 56.73

See More

52-Week High 66.41
Fibonacci 61.8% 61.22
Fibonacci 50% 59.62
Last Price 59.14
Fibonacci 38.2% 58.02
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar